KLOW Blend Historical Development of Constituent Peptides

BPC-157 was first isolated and characterized from gastric juice by Professor Predrag Sikirić and colleagues at the University of Zagreb, Croatia, in the early 1990s.^[1] The compound (CAS 137525-51-0; also designated PL 14736) was identified as a 15-amino acid partial sequence of the endogenous protection compound protein, exhibiting cytoprotective properties in gastric mucosal models. Its stability relative to other bioactive peptides-attributable to its proline-rich central motif-facilitated investigation across a range of murine tissue systems.^[3]

TB-500 is a synthetic heptapeptide corresponding to residues 17–23 of full-length thymosin beta-4 (β4), a ubiquitous 43-amino acid G-actin sequestering protein originally isolated from bovine thymus in the 1960s.^[4][6] The designation TB-500 refers to the acetylated active fragment Ac-LKKTETQ, which retains the actin-binding motif of the parent molecule. The full-length β4 molecule underpins the preponderance of the published academic literature, with TB-500 used in research contexts to access this actin-regulatory biology.^[4]

GHK-Cu was isolated from plasma by Pickart in 1973, originally identified as a factor within the albumin fraction that induced aged liver cells to synthesize proteins with a profile resembling that of younger tissue.^[7] Subsequent investigations established that this activity resided in the tripeptide glycyl-L-histidyl-L-lysine, which forms a stable chelate with copper(II) ions (GHK-Cu). Research has since characterized GHK-Cu as a regulator of ECM synthesis, collagen production, and tissue remodeling processes.^[7][8]

KPV (Lys-Pro-Val) corresponds to C-terminal residues 11–13 of α-melanocyte-stimulating hormone (α-MSH), a 13-amino acid neuropeptide of pituitary origin. Research investigations identified that this tripeptide fragment retains the anti-inflammatory activity of the parent hormone while lacking its pigmentation-inducing and hunger hormone-modulating implications.^[10][11] The small molecular size of KPV may confer oral stability and facilitate intracellular entry via di/tripeptide transporters, properties that have been examined in gastrointestinal and inflammatory research models.

 

KLOW Blend Receptor Mechanisms and Intracellular Signaling

BPC-157 engages VEGFR2 (vascular endothelial growth factor receptor 2), a receptor tyrosine kinase expressed on endothelial cells. VEGFR2 activation may initiate downstream phosphorylation cascades through the Akt-eNOS axis, promoting nitric oxide (NO) synthesis and endothelial cell proliferation.^[2] Separately, BPC-157 has been observed to activate the focal adhesion kinase (FAK)-paxillin pathway in tendon fibroblasts, a signaling axis associated with increased cell migration and cytoskeletal reorganization.^[1] Research suggests BPC-157 may also upregulate growth hormone receptor expression in fibroblast populations, potentially potentiating GH-mediated repair signaling.^[3]

TB-500’s primary mechanism involves sequestration of monomeric G-actin, maintaining the intracellular pool of actin in a polymerization-competent state and enabling rapid cytoskeletal reorganization during cell migration.^[6] Integrin-linked kinase (ILK) activation represents a downstream consequence of TB-500/β4 exposure in cardiac and endothelial cells, initiating Akt-mediated survival signaling.⁵ In cardiac injury models, ILK and Akt upregulation following β4 exposure has been associated with supported early cardiomyocyte survival and neovascularisation.

GHK-Cu engages fibroblasts and dermal cells to upregulate matrix metalloproteinase-2 (MMP-2), an enzyme involved in ECM remodeling and turnover of fibrillar collagen.^[8] Concurrently, GHK-Cu may stimulate synthesis of type I collagen, elastin, and sulfated glycosaminoglycans – key structural ECM components. Research suggests these dual MMP-upregulatory and collagen-stimulatory implications might indicate a coordinated ECM remodeling capacity, consistent with its historical characterization as a wound recovery activator.

KPV enters intestinal epithelial cells and immune cells primarily through the PepT1 di/tripeptide transporter, an uptake mechanism that is upregulated in inflamed intestinal tissue during inflammatory bowel conditions. Once internalized, KPV mitigates NF-κB nuclear translocation by attenuating IkB-α degradation, thereby reducing transcriptional activation of pro-inflammatory cytokine genes including IL-8, TNF-α, and IL-1β.^[10][11] Research suggests this intracellular NF-κB mitigation may operate independently of melanocortin receptor (MCR) engagement, distinguishing its mechanism from the parent α-MSH molecule.

 

KLOW Blend Scientific and Research Studies

 

BPC-157: FAK-Paxillin Pathway Activation and Tendon Fibroblast Biology

Researchers studied the mechanistic basis of BPC-157’s implications on tendon recovery using cultured murine model Achilles tendon fibroblasts and tendon explant outgrowth assays.^[1] BPC-157 significantly accelerated the outgrowth of tendon fibroblasts from explant cultures and markedly increased in vitro fibroblast migration in a concentration-dependent manner. Cell proliferation, as measured by MTT assay, was not directly altered, suggesting that the primary implication may involve cell motility and tissue invasion rather than proliferative expansion.

Western blot analysis indicated that BPC-157 produced concentration-dependent increases in the phosphorylation of FAK and paxillin-key components of focal adhesion complexes-without altering total protein levels. FITC-phalloidin staining further suggested supported F-actin formation in BPC-157-treated fibroblasts. Research suggests these findings might indicate that BPC-157 promotes tendon cell migration and structural reorganization through activation of the FAK-paxillin focal adhesion pathway, potentially contributing to observed accelerations in tendon wound recovery in preclinical models.

 

BPC-157: VEGFR2-Mediated Angiogenesis and Vascular Signaling

Hsieh et al. (2017)^[2] examined the angiogenic signaling mechanisms of BPC-157 in endothelial cell models and correlated receptor-level activity with vascular outcomes. Findings suggested that BPC-157 may upregulate VEGFR2 expression in endothelial cells and activate downstream Akt-eNOS phosphorylation cascades, which are associated with endothelial nitric oxide production and angiogenic sprouting. These receptor-level observations were correlated with supported vessel formation markers in the murine models studied.

Brcic et al. (2009)^[3] examined the angiogenic potential of BPC-157 across muscle tissue and murine tendon recovery research models, correlating peptide exposure with VEGF expression using cell culture and animal systems. Observations suggested that BPC-157 may stimulate angiogenesis by upregulating VEGF expression at wound sites, with the angiogenic response appearing closely associated with the recovery progression documented histologically across tissue compartments. Research suggests these findings might indicate that VEGFR2-driven angiogenesis represents a mechanistically central element of BPC-157’s tissue repair activity in preclinical settings.

 

TB-500 (Thymosin Beta-4): ILK-Akt Activation and Cardiac Cell Survival

Bock-Marquette et al. (2004)^[5] studied the role of thymosin beta-4 in cardiac cell biology following myocardial injury. In a murine coronary artery ligation model, β4 exposure was associated with upregulation of integrin-linked kinase (ILK) and Akt activity within the cardiac tissue. supported early cardiomyocyte survival was observed in treated animals, alongside support for cardiac functional parameters relative to control groups.

The investigators further characterized β4’s implications on cardiac progenitor cell migration in vitro, finding that the peptide promoted cardiomyocyte migration through ILK-dependent pathways. Research suggests these findings might indicate that β4-mediated ILK-Akt signaling may represent a cardioprotective mechanism with potential relevance to preclinical models of ischemic cardiac injury. These observations provide mechanistic context for TB-500’s G-actin-based biology in cardiac tissue, where cytoskeletal regulation is central to cell migration and structural repair.

 

TB-500 (Thymosin Beta-4): Epicardial Progenitor Mobilization and Neovascularisation

Smart et al. (2007)^[12] examined the capacity of thymosin beta-4 to mobilize adult epicardial progenitor cells and stimulate neovascularisation in a murine cardiac injury model. Following myocardial infarction, β4 exposure was associated with reactivation of dormant epicardial progenitor populations and promotion of new coronary vessel formation. The investigators proposed that β4 may stimulate the re-expression of embryonic epicardial genes, enabling adult epicardial cells to contribute to vascular repair processes.

Actin regulation by the β4 molecule was identified as integral to the progenitor mobilization response, linking the peptide’s primary biochemical function (G-actin sequestration) to downstream biological outcomes in a clinically relevant injury model. Research suggests these findings might indicate that TB-500’s actin-regulatory mechanism may drive paracrine and regenerative signalling beyond the immediate site of peptide engagement.

 

GHK-Cu: ECM Remodeling, Collagen Synthesis, and Glycosaminoglycan Production

Researchers conducted a comprehensive review^[7] of GHK-Cu’s biological activity across dermatology and wound biology models. Investigations cited therein indicated that GHK-Cu may stimulate collagen synthesis in fibroblast cultures, accelerate wound contraction and epithelialization, and promote the take of transplanted dermal cells in murine models. The review further identified GHK-Cu’s capacity to upregulate MMP-2 expression, facilitating ECM remodeling and clearance of damaged matrix proteins. Endogenous plasma GHK concentrations of approximately 200 ng/mL at age 20 were reported to decline to approximately 80 ng/mL by age 60, with this decline noted to correlate with observed reductions in tissue regenerative capacity.

Scientists^[8] examined the role of matrikines-ECM-derived peptide fragments including GHK-in the regulation of ECM degradation and synthesis. Findings supported the characterization of GHK as a matrikine capable of modulating MMP expression and promoting glycosaminoglycan synthesis in wound tissue models, implications potentially relevant to the maintenance of structural ECM integrity during repair processes. Research suggests these findings might indicate that GHK-Cu may function as an endogenous ECM regulatory signal with broad relevance to tissue homeostasis research.

 

GHK-Cu: Anti-Inflammatory Activity in Acute Tissue Injury Models

Research was conducted studying the implications of GHK-Cu in a murine model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). GHK-Cu exposure was associated with suppression of pro-inflammatory mediators including reactive oxygen species (ROS), nitric oxide (NO), and cyclooxygenase-2 (COX-2) in pulmonary tissue. Reductions in transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) concentrations were also reported in treated animals relative to untreated controls.^[9]

Histopathological evaluation of lung tissue suggested reduced inflammatory infiltrate and structural preservation in GHK-Cu-exposed groups. Research suggests these observations might indicate that GHK-Cu may engage anti-inflammatory pathways beyond its ECM-regulatory function, potentially through modulation of iron-mediated oxidative stress and cytokine regulatory networks. These findings may complement the anti-inflammatory mechanism of KPV within the KLOW blend by providing an additional, mechanistically distinct pathway of inflammatory modulation.

 

KPV: PepT1-Mediated Uptake and NF-κB Mitigation in Intestinal Inflammation Models

Dalmasso et al. (2008)^[10] studied the mechanism underlying KPV’s anti-inflammatory activity in intestinal epithelial and immune cell models. Using intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and Jurkat T cells stimulated with pro-inflammatory cytokines, the investigators examined whether KPV’s anti-inflammatory implication required the PepT1 di/tripeptide transporter. Uptake experiments using radiolabelled [3H]KPV and competitive mitigation assays confirmed PepT1-mediated intracellular entry in PepT1-expressing cells.

Mechanistic assays indicated that KPV attenuated NF-κB-dependent gene expression by mitigating IkB-α degradation, with downstream reductions in IL-8 mRNA expression. In two murine colitis models (DSS-induced and CD45RBhi transfer colitis), systemic KPV exposure was associated with attenuation of colonic inflammation, as assessed by histological scoring and cytokine measurement. Research suggests these findings might indicate that PepT1-mediated intracellular delivery may be a prerequisite for KPV’s anti-inflammatory activity in epithelial tissues, and that upregulation of PepT1 during intestinal inflammation may support local peptide uptake at inflamed mucosal sites.

 

KPV: Melanocortin-Derived Anti-Inflammatory Activity in IBD Models

Scientists evaluated KPV’s potential in two established murine intestinal inflammation models: DSS-induced colitis and CD45RBhi transfer colitis. The study additionally examined KPV activity in animals carrying a non-functional melanocortin-1 receptor (MC1Re/e), enabling dissection of receptor-dependent from receptor-independent anti-inflammatory mechanisms.^[11]

Findings suggested that KPV attenuated clinical and histological indices of colitis in both models, and that this anti-inflammatory activity was preserved in MC1R-deficient animals. Research suggests these results might indicate that KPV’s gastrointestinal anti-inflammatory mechanism may not require functional MCR engagement, consistent with the NF-κB-centric, receptor-independent intracellular pathway characterized by Dalmasso et al.^[11] The mechanistic independence of KPV from its parent hormone’s receptor may have implications for the design of research models investigating targeted mucosal anti-inflammatory signaling.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672. Available from: https://pubmed.ncbi.nlm.nih.gov/21030672/
2. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. Available from: https://link.springer.com/article/10.1007/s00109-016-1488-y
3. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60(Suppl 7):191-196. Available from: https://www.researchgate.net/publication/51443032
4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID: 22136436. Available from: https://pubmed.ncbi.nlm.nih.gov/22136436/
5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03040. PMID: 15565145. Available from: https://pubmed.ncbi.nlm.nih.gov/15565145/
6. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. doi:10.1016/s1357-2725(00)00087-x. PMID: 11311852. Available from: https://pubmed.ncbi.nlm.nih.gov/11311852/
7. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/
8. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the regulation of extracellular matrix degradation. Biochimie. 2005;87(3-4):353-360. doi:10.1016/j.biochi.2004.10.013. PMID: 15781325. Available from: https://pubmed.ncbi.nlm.nih.gov/15781325/
9. Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. doi:10.18632/oncotarget.11168. PMID: 27542263. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295439/
10. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID: 18061177. Available from: https://www.gastrojournal.org/article/S0016-5085(07)01852-5/fulltext
11. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. Available from: https://academic.oup.com/ibdjournal/article-abstract/14/3/324/4653598
12. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Bhatt DL, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularisation. Nature. 2007;445(7124):177-182. doi:10.1038/nature05383. PMID: 17187048. Available from: https://pubmed.ncbi.nlm.nih.gov/17187048/

Copper peptides are a class of naturally occurring and synthetically reproduced small peptide and copper ion complexes in which Cu²⁺ coordinates with specific amino acid sequences to form stable chelate structures. Three members of this class have received the most extensive research attention: glycyl-L-histidyl-L-lysine copper(II) (GHK-Cu), aspartyl-alanyl-histidyl-lysine copper(II) (DAHK-Cu), and alanyl-histidyl-lysine copper(II) (AHK-Cu). Each exhibits a distinct coordination chemistry, tissue distribution, and functional profile in preclinical research models.^[1][2][4]

GHK-Cu is the most extensively characterized member of this class. It is a tripeptide originally isolated from plasma albumin fractions and subsequently detected in saliva, urine, and wound fluid.^[11][6] Research has attributed broad biological activity to GHK-Cu, encompassing extracellular matrix (ECM) remodelling, gene expression modulation, antioxidant pathway activation, wound repair facilitation, and neuromodulatory effects in preclinical models.^[13]

DAHK-Cu is a tetrapeptide corresponding to the N-terminal copper-binding domain of serum albumin, studied principally for its role in copper(II) transport, redox regulation, and neuroprotective signalling.^[2] AHK-Cu (PubChem CID 168431292) is a tripeptide investigated for its capacity to stimulate dermal fibroblast activity, modulate growth factor expression, and influence follicular biology.^[4][13]

 

Copper Peptides Historical Development

GHK-Cu was first isolated in 1973 by Pickart and Thayer, who identified a plasma albumin-derived tripeptide fraction capable of stimulating protein synthesis in aged liver tissue to levels characteristic of younger tissue.^[1] This seminal observation established the conceptual basis for GHK-Cu as a biological signalling molecule associated with tissue maintenance and cellular rejuvenation. Subsequent characterization confirmed GHK’s high affinity for cupric ions (Cu²⁺), and the resulting copper complex (GHK-Cu) was found to be the biologically active species.¹ Research suggests that plasma GHK-Cu concentrations may decline over time from approximately 200 ng/mL in the first 25% of life to approximately 80 ng/mL by the 70%, a trajectory that might suggest a functional association between GHK-Cu availability and time-related tissue repair capacity.^[1]

Interest in the broader copper peptide class subsequently expanded. DAHK-Cu was identified as the N-terminal copper-binding sequence of serum albumin and investigated computationally and biochemically for its coordination geometry and redox properties.^[2] AHK-Cu emerged from applied research into dermatological active ingredients, with preclinical investigations examining its effects on fibroblast proliferation and hair follicle biology.^[4][13]

Early cellular biology investigations in the 1980s established that GHK-Cu could stimulate collagen synthesis in fibroblast cultures and subsequent decades of research extended the characterization of this class into wound repair, oncological, neurological, pulmonary, and skin biology research contexts.

 

Copper Peptides Coordination Chemistry and Proposed Mechanisms of Action

The biological activity of copper peptides is thought to arise primarily from their ability to coordinate and mobilize Cu²⁺ ions within the extracellular environment, modulating intracellular signalling cascades through copper-dependent enzymatic and transcriptional pathways.^[13]

GHK-Cu coordinates Cu²⁺ through the imidazole nitrogen of the histidine residue, the terminal α-amino group, and deprotonated amide nitrogen atoms of the peptide backbone, forming a square-planar chelate geometry. This geometry is thought to influence the redox state of coordinated copper, potentially enabling participation in both oxidative and reductive cellular reactions.^[1]

Research suggests DAHK-Cu exhibits distinct coordination behaviour attributable to the aspartyl residue at its N-terminus, which may contribute to carboxylate-mediated chelation alongside histidine imidazole coordination.^[2] Computational modelling suggests DAHK-Cu may adopt multiple stable copper-binding configurations, with relative stability influenced by solvent environment and pH. These properties position DAHK-Cu as a potentially relevant species in albumin-mediated copper transport and in redox biology research contexts.

AHK-Cu has been investigated for its potential to modulate vascular endothelial growth factor (VEGF) and TGF-β1 expression in fibroblast and endothelial cell cultures, with research suggesting potential regulatory roles in angiogenesis and ECM remodelling.^[4]

 

Copper Peptides Scientific and Research Studies

 

GHK-Cu and Extracellular Matrix Biology: Collagen Synthesis and Matrix Metalloproteinase Regulation

Foundational research by Maquart et al. (1988)^[5] characterized the perceived effects of GHK-Cu on collagen synthesis in primary fibroblast cultures. GHK-Cu exposure at nanomolar concentrations was associated with measurable increases in collagen production relative to untreated control cultures, establishing a precedent for the peptide’s potential role as a fibroblast-activating signal. These early observations prompted investigation into the ECM regulatory mechanisms through which GHK-Cu might exert its effects.

Subsequent investigations by Siméon et al. (2000)^[6] extended this characterization to matrix metalloproteinase (MMP) biology. GHK-Cu exposure in fibroblast cultures was associated with elevated matrix metalloproteinase-2 (MMP-2) expression, alongside concurrent up-regulation of tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2). Research suggests this dual regulatory pattern appear to show that GHK-Cu participates in a coordinated ECM remodelling response, in which controlled MMP-mediated matrix degradation is balanced by TIMP-mediated inhibition to preserve matrix structural integrity. These findings may inform the study of age-related changes in ECM homeostasis and wound-associated tissue remodelling processes.^[6]
 

GHK-Cu and Wound Repair: Comparative Preclinical Models

A controlled study by Cangul et al. (2006)^[7] evaluated GHK-Cu against zinc oxide in a standardized open-wound model using 18 New Zealand White rabbits divided into three groups: GHK-Cu, zinc oxide, and placebo. Wound assessments were conducted over a 21-day period following standardized wound induction. The investigators reported that the GHK-Cu group exhibited significantly greater mean wound contraction relative to both the zinc oxide and placebo groups, and concluded that the tripeptide-copper complex may represent a more effective choice within wound care research protocols compared to zinc oxide under the conditions studied.^[7]

A follow-up investigation by Gul et al. (2008)^[8] compared GHK-Cu with helium-neon laser therapy at energy levels of 1 J/cm² and 3 J/cm² across 24 New Zealand White rabbits over a 28-day wound monitoring period. Post-experimental histological analysis suggest that subjects receiving GHK-Cu exhibited reduced neutrophil infiltration indicative of attenuated inflammatory response and increased neovascularization, potentially reflecting accelerated tissue regeneration. Research suggests these findings might suggest complementary anti-inflammatory and pro-angiogenic properties of GHK-Cu in wound repair contexts.^[8]

 

GHK-Cu in Neuropathic Ulcer Models

A controlled trial by Mulder et al. (1994)^[9] evaluated GHK-Cu peptide complex gel in subjects with neuropathic plantar ulcers, employing a randomized placebo-controlled design with a standardized sharp debridement protocol. Subjects allocated to the GHK-Cu gel group exhibited wound closure rates exceedingly high, compared to relatively lower rate in the placebo control group.^9] Research suggests these findings might show that GHK-Cu engagement of tissue remodelling and cellular regeneration pathways may produce measurable improvements in wound resolution relative to standard care in neuropathic ulcer models.

 

GHK-Cu and GHK-Cu-Loaded Biomaterial Dressings: Wound Healing Research

A recent investigation by Wang et al. (2024)^[15] developed and evaluated an electrospun GHK-Cu/pionin-loaded polyvinyl butyral/polyvinylpyrrolidone (PVB/PVP) smart wound dressing in a controlled wound healing model. The composite dressing was designed to enable controlled release of GHK-Cu from a fibrous scaffold matrix. Outcomes assessed included oxidative stress markers, inflammatory cytokine profiles, antimicrobial activity, and tissue regenerative endpoints across wound closure assessments.^[15]

Research suggests that the GHK-Cu-loaded composite dressing was associated with accelerated wound closure, reduced pro-inflammatory cytokine expression, decreased oxidative stress markers, and enhanced tissue regeneration relative to control dressings. The investigators proposed that GHK-Cu’s anti-oxidant, anti-inflammatory, and ECM-modulatory properties may be delivered in a sustained, localized manner through electrospun scaffold integration. Research suggests these findings suggest that GHK-Cu-functionalized biomaterial platforms could represent a relevant direction for investigating advanced wound care systems in preclinical models.

 

GHK-Cu and Antioxidant and Anti-inflammatory Signalling in Pulmonary Models

Research by Zhang et al. (2022)^[10] examined the potential of GHK-Cu in murine models exposed to cigarette smoke (CS), evaluating pro-inflammatory cytokine expression, neutrophil-mediated inflammatory indices, and oxidative stress biomarkers in pulmonary tissue. Findings appear to show that GHK-Cu exposure was associated with reductions in bronchoalveolar lavage concentrations of interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α), and with attenuation of myeloperoxidase (MPO) activity in lung tissue.^[10]

 

GHK-Cu and Neuromodulatory Biology: Anxiety, Aggression, and Pain

Preclinical behavioural investigations have explored the neuromodulatory properties of GHK-Cu across multiple experimental paradigms. Bobyntsev et al. (2015)^[11] evaluated any anxiolytic effects using an elevated plus maze model in rodents, a validated paradigm in which increased open-arm exploration reflects reduced anxiety-like behaviour. GHK-Cu-exposed animals reportedly exhibited significant changes in anxiety-related behavioural measures relative to untreated controls, with the pattern of results interpreted as potentially consistent with anxiolytic activity.^[11]

Another research^[12] examined GHK effects on pain-induced aggressive-defensive behaviour in a rodent model employing mild electrical stimulation to provoke aggression between paired animals. Exposure to the Gly-His-Lys peptide sequence 12 minutes prior to stimulation was associated with an approximately fivefold reduction in aggressive interaction frequency relative to untreated controls.^[12] Research suggests these observations speculate that GHK-Cu may modulate stress-induced behavioural responses through neuromodulatory mechanisms, though the specific receptor and signalling pathways underlying these preclinical findings warrant further mechanistic characterization.

 

GHK-Cu and Cognitive Resilience in Aged Animal Models

A recent preprint investigation by Tucker et al. (2023)^[14] examined the potential of intranasal GHK-Cu on cognitive performance and neuroinflammatory markers in aged C57BL/6 mice at 20 months of age. The experimental model involved twice-daily intranasal GHK-Cu exposure over a two-month period, with cognitive performance evaluated using spatial memory and learning navigation tasks, and neurobiological outcomes assessed through markers of neuroinflammation and axonal integrity.

Findings suggested that aged mice receiving GHK-Cu exhibited enhanced cognitive performance in spatial memory and learning navigation tasks relative to saline-treated controls. Additionally, neuroinflammatory marker expression and axonal damage indices were reduced in GHK-Cu-treated animals compared to controls.^[14] Research suggests these preliminary observations might suggest that GHK-Cu engagement of antioxidant and anti-inflammatory pathways may extend to the central nervous system, and that copper peptide signalling could represent a relevant target for investigating age-associated cognitive decline in preclinical models. The authors note that further peer-reviewed investigation is warranted to confirm and extend these findings.

 

AHK-Cu: Dermal Fibroblast Activation, Collagen Synthesis, and Hair Follicle Biology

AHK-Cu has been investigated in dermatological and follicular biology research contexts. Preclinical data reviewed by Patt et al.^[4] suggest that AHK-Cu may stimulate collagen synthesis in dermal fibroblast models, with observed increases in collagen and elastin production associated with enhanced dermal matrix density in animal models. The proposed mechanism involves AHK-Cu-mediated modulation of VEGF and TGF-β1 expression, with downstream activation of both fibroblasts which produce structural matrix proteins and endothelial cells, which support vascular network formation in regenerating tissue.^[4]

 

DAHK-Cu: Computational Characterization and Redox Biology

Milner et al. (2021)² conducted a computational study of copper binding to the DAHK tetrapeptide using molecular modelling approaches to characterize the coordination geometry, binding energy landscape, and electronic properties of the DAHK-Cu complex. Findings reportedly suggest that DAHK may adopt multiple stable Cu²⁺ coordination configurations, with the aspartyl carboxylate and histidyl imidazole residues contributing to a flexible multi-dentate coordination environment.² Research suggests these computational findings might suggest that DAHK-Cu’s structural flexibility could enable dynamic participation in copper ion transport and redox cycling processes in albumin-mediated copper homeostasis, with potential implications for the study of copper dysregulation in oxidative stress and neurodegenerative research contexts.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
2. Milner A, Alshammari N, Platts JA. Computational study of copper binding to DAHK peptide. Inorganica Chimica Acta. 2021;528:120589. doi:10.1016/j.ica.2021.120589. Available from: https://doi.org/10.1016/j.ica.2021.120589
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. doi:10.1155/2014/151479. PMID: 25302294. Available from: https://pubmed.ncbi.nlm.nih.gov/25302294/
4. Patt LM. Neova DNA Repair Factor Nourishing Lotion Stimulates Collagen and Speeds Natural Repair Process. Procyte/Neova Clinical Study Report. Available from: https://www.dermacaredirect.co.uk/skin/frontend/default/dermacare/pdf/neova-dna-nourishing-study.pdf
5. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. Available from: https://pubmed.ncbi.nlm.nih.gov/3169264/
6. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. doi:10.1016/s0024-3205(00)00803-1. PMID: 11045606. Available from: https://pubmed.ncbi.nlm.nih.gov/11045606/
7. Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol. 2006;17(6):417-23. doi:10.1111/j.1365-3164.2006.00551.x. PMID: 17083573. Available from: https://pubmed.ncbi.nlm.nih.gov/17083573/
8. Gul NY, Topal A, Cangul IT, Yanik K. The effects of tripeptide copper complex and helium-neon laser on wound healing in rabbits. Vet Dermatol. 2008;19(1):7-14. doi:10.1111/j.1365-3164.2007.00647.x. PMID: 18177285. Available from: https://pubmed.ncbi.nlm.nih.gov/18177285/
9. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. doi:10.1046/j.1524-475X.1994.20406.x. PMID: 17147644. Available from: https://pubmed.ncbi.nlm.nih.gov/17147644/
10. Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022;9:925700. doi:10.3389/fmolb.2022.925700. Available from: https://doi.org/10.3389/fmolb.2022.925700
11. Bobyntsev II, Chernysheva OI, Dolgintsev ME, Smakhtin MY, Belykh AE. Anxiolytic effects of Gly-His-Lys peptide and its analogs. Bull Exp Biol Med. 2015;158(6):726-8. doi:10.1007/s10517-015-2847-3. PMID: 25900608. Available from: https://pubmed.ncbi.nlm.nih.gov/25900608/
12. Sever’yanova LA, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017;164(2):140-143. doi:10.1007/s10517-017-3943-3. PMID: 29181666. Available from: https://pubmed.ncbi.nlm.nih.gov/29181666/
13. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on hair growth in vitro. Arch Pharm Res. 2007;30(7):834-9. doi:10.1007/BF02978833. PMID: 17703734. Available from: https://pubmed.ncbi.nlm.nih.gov/17703734/
14. Tucker M, Keely A, Park JY, Rosenfeld M, Wezeman J, Mangalindan R, Ratner D, Ladiges W. Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv [Preprint]. 2023 Nov 17:2023.11.16.567423. doi:10.1101/2023.11.16.567423. PMCID: PMC10680828. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/
15. Wang Y, Zheng Z, Pathak JL, Cheng H, Huang S, Fu Z, Li P, Wu L, Zheng H. GHK-Cu/pionin-loaded in situ electrospun PVB/PVP smart dressing promotes wound healing via anti-oxidant, anti-inflammatory, antimicrobial, and tissue regenerative effects. Chem Eng J. 2024;492:152154. doi:10.1016/j.cej.2024.152154. Available from: https://doi.org/10.1016/j.cej.2024.152154
16. National Center for Biotechnology Information. PubChem Compound Summary for CID 133697840, GHK-Cu. 2025. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu
17. National Center for Biotechnology Information. PubChem Compound Summary for CID 168431292, AHK-Cu. 2025. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/168431292

The Modified GRF 1-29 and GHRP-2 peptide blend is a dual-component research formulation combining a stabilized growth hormone-releasing hormone (GHRH) analog with a synthetic ghrelin-mimetic hexapeptide. Modified GRF 1-29 (also designated CJC-1295 without DAC, or tetra-substituted GRF(1-29)) targets the GHRH receptor (GHRH-R), a Class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells.^[1][3]

GHRP-2 (Pralmorelin; KP-102) is a synthetic hexapeptide agonist of the ghrelin receptor subtype GHS-R1a.^[2][4] Each constituent engages a pharmacologically distinct receptor system, enabling concurrent investigation of complementary intracellular signaling cascades governing growth hormone (GH) synthesis and secretion within the somatotroph population.

Research suggests that combined stimulation of GHRH-R and GHS-R1a may produce GH secretory responses that exceed those attributable to single-receptor engagement,^[5] and that this receptor pair may represent mechanistically distinct but convergent regulatory inputs at the anterior pituitary level.^[3][4] The non-redundant architecture of this blend may support investigation of somatotroph gene expression, receptor regulation, second messenger pathway integration, and neuroendocrine feedback dynamics across controlled laboratory settings.

The Fragment 176-191, Modified GRF 1-29, and Ipamorelin peptide blend is a research-grade tri-component formulation combining three structurally and mechanistically distinct synthetic peptides. Fragment 176-191 (also designated hGH Frag 176-191, AOD-9604, or Tyr-hGH 177-191) is a synthetic C-terminal hexadecapeptide fragment of human growth hormone (hGH), engineered to isolate the lipolytic domain of the hGH polypeptide.^[1][5] Modified GRF 1-29 (CJC-1295 without DAC; tetra-substituted GRF(1-29)) is a structurally stabilized analog of the biologically active N-terminal 29-residue fragment of growth hormone-releasing hormone (GHRH), targeting the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells.^[6][9] Ipamorelin (NNC 26-0161) is a synthetic pentapeptide and selective agonist of the ghrelin receptor subtype GHS-R1a.^[10]

Each constituent operates through a pharmacologically distinct receptor system. Fragment 176-191 engages adipocyte metabolic pathways independently of the canonical hGH receptor and without measurable IGF-1 stimulation.^[12] Modified GRF 1-29 activates GHRH-R via Gαs-coupled cAMP-PKA signaling.^[6] Ipamorelin engages GHS-R1a via Gq/G11-mediated phospholipase C (PLC) activation and intracellular calcium mobilization.^[10] This tri-modal receptor architecture may support concurrent investigation of adipocyte lipolysis, pituitary somatotroph regulation, and ghrelin-axis pharmacology within a unified experimental framework.

 

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Beldn Receptor Mechanisms and Intracellular Signaling

Fragment 176-191 is proposed to stimulate adipose tissue lipolysis and mitigate lipogenesis through mechanisms that are partially β₃-adrenergic receptor (β₃-AR)-mediated and partially independent of adrenergic engagement.¹ Research suggests the peptide may upregulate β₃-AR expression in adipocytes, potentially heightening cellular sensitivity to endogenous catecholamines and promoting hormone-sensitive lipase (HSL) activation. Additionally, research in receptor knock-out models indicates that lipolytic activity may persist in the absence of functional β₃-AR, implicating supplementary energy expenditure and fat oxidation pathways.¹ Critically, studies suggest Fragment 176-191 does not engage the canonical hGH receptor and does not measurably elevate IGF-1 or impair glucose tolerance. ^[2][3]

Modified GRF 1-29 binds GHRH-R, a Class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotroph cells. Receptor engagement activates Gαs-mediated adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP). PKA-mediated phosphorylation of downstream transcription factors may augment GH gene transcription and the amplitude of pulsatile GH secretory events.^[6][7] The four structural substitutions within Modified GRF 1-29 are thought to confer resistance to DPP-IV-mediated cleavage, potentially extending implicationive receptor engagement relative to the unmodified GRF(1-29) sequence while preserving a physiologically plausible pulsatile pharmacokinetic profile.⁶

Ipamorelin activates GHS-R1a, a constitutively active GPCR expressed on pituitary somatotroph cells and in hypothalamic nuclei. GHS-R1a engagement initiates Gq/G11-mediated PLC activation, producing inositol 1,4,5-trisphosphate (IP₃) and mobilizing intracellular calcium stores, culminating in GH vesicle exocytosis.^[10] The concurrent engagement of GHRH-R (via Modified GRF 1-29) and GHS-R1a (via Ipamorelin) at the somatotroph membrane may provide a convergent cAMP-dependent and calcium-dependent intracellular signaling environment, which research suggests might amplify GH secretory responses beyond those achievable by single-receptor stimulation.^[6][10]

 

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend Scientific Research and Studies

 

Fragment 176-191: Lipolytic Activity in Obese Rodent and Receptor Knock-Out Models

A foundational preclinical investigation^[1] examined the chronic implications of Fragment 176-191 on lipid metabolism in obese murine models and in genetically modified mice lacking functional β₃-adrenergic receptors (β₃-AR knock-out murine models). Following 14 days of exposure, obese mice receiving Fragment 176-191 exhibited reductions in overall weight and fat accumulation relative to controls, with concurrent increases in β₃-AR RNA expression in adipose tissue. The investigators proposed that β₃-AR upregulation might contribute to heightened lipolytic sensitivity in adipocytes.

To determine whether β₃-AR expression was a necessary prerequisite for the observed implications, the study extended to β₃-AR knock-out models. Research findings suggested that Fragment 176-191 retained lipolytic activity in receptor-null animals, implicating receptor-independent pathways, potentially involving augmented energy expenditure and fat oxidation mechanisms, in the peptide’s metabolic profile. These observations might indicate that Fragment 176-191 engages multiple adipocyte signaling pathways rather than operating through a single receptor-mediated mechanism.

 

Fragment 176-191: Metabolic Studies in Obese Murine Models

An investigation^[2] employing obese murine models as a validated preclinical model of hyperphagia and leptin receptor deficiency evaluated metabolic parameters following chronic Fragment 176-191 exposure over 19 days. Findings suggested that treated animals exhibited substantially reduced overall weight gain relative to untreated controls, with investigators reporting overall weight gain reductions exceeding 50% in the treatment cohort.

Biochemical analyses of adipose tissue from treated animals indicated elevated lipolytic activity within adipocytes. Parameters of insulin sensitivity remained largely unchanged relative to controls, consistent with the hypothesis that Fragment 176-191 exerts metabolic implications through pathways distinct from those engaged by intact hGH.^[2] Research suggests these observations might indicate selective adipocyte targeting with a metabolic profile that differs substantially from full-length hGH, which produces insulin resistance at comparable biological concentrations in preclinical settings.

 

Fragment 176-191: Tolerability Profiling

A pooled analysis^[3] aggregating data from six randomized, double-blind, placebo-controlled trials involving 893 adult subjects evaluated the tolerability profile of Fragment 176-191 across varying experimental concentrations. Findings indicated that serum IGF-1 concentrations were not significantly altered by Fragment 176-191 relative to placebo across the pooled trial population, consistent with the hypothesis that the peptide does not engage the canonical hGH receptor. Oral glucose tolerance evaluation across the combined study population indicated no adverse support for carbohydrate metabolism. No anti-peptide antibodies were detected in subjects selected for immunogenicity evaluation, and no serious adverse events attributable to the compound were recorded across any of the included trials.

A dedicated genotoxicological and pharmacokinetic characterization study^[4] assessed Fragment 176-191 across an Ames mutagenicity evaluation, a chromosomal aberration assay in CHO cells, and a bone micronucleus assay. No data showed genotoxic activity identified across any assay system. Chronic oral toxicology studies in murine models (6 months) and cynomolgus monkeys (9 months) found no treatment-related adverse clinical signs or significant histological findings at the concentrations examined.⁴ Research suggests this characterization might support the compound’s ongoing investigational relevance in metabolic research contexts.

 

Modified GRF 1-29: GHRH-R Pharmacology and GH-IGF-1 Axis Stimulation

Preclinical investigations^[6] examining the pharmacological properties of tetrasubstituted hGRF(1-29) bioconjugates in murine anterior pituitary preparations provided early characterization of the structural class underlying Modified GRF 1-29. Receptor binding studies suggested that the tetrasubstituted scaffold may activate GHRH-R with affinities consistent with those of the unmodified GRF(1-29) sequence, while exhibiting better-supported resistance to enzymatic degradation. The research identified CJC-1295 as a long-lasting GRF analog, providing a foundational pharmacological context for the Modified GRF 1-29 scaffold.

A dual randomized, placebo-controlled, double-blind ascending-concentration investigation^[7] evaluated the pharmacokinetic profile and pharmacodynamic implications of CJC-1295, the structural relative of Modified GRF 1-29, in functional research models over study durations of 28 and 49 days. Following single exposures, mean plasma GH concentrations increased by 2- to 10-fold relative to baseline and remained elevated for 6 days or more. Mean plasma IGF-1 concentrations increased by 1.5- to 3-fold, persisting for 9-11 days.

After multiple exposures, mean IGF-1 levels remained above baseline for up to 28 days, with data of a cumulative implication across successive exposures. Research suggests these pharmacodynamic findings might indicate that structural stabilization of the GRF(1-29) scaffold may produce sustained GHRH-R engagement and prolonged GH-IGF-1 axis stimulation relative to endogenous GHRH.

 

Modified GRF 1-29: Somatotroph Biology in GHRH Knock-Out Models

A preclinical investigation^[8] in GHRH knock-out (GHRHKO) mice examined whether once-daily exposure to CJC-1295, structurally representative of the Modified GRF 1-29 class, might normalize overall composition and GH-axis parameters in animals lacking endogenous GHRH signaling. Findings suggested that GHRHKO animals receiving daily exposures exhibited overall weight and skeletal measurements comparable to wild-type controls, while animals receiving less frequent exposures showed partial, incomplete normalization.

Molecular analyses indicated that CJC-1295 exposure was associated with increases in total pituitary RNA and GH mRNA, and immunohistochemical evaluations were interpreted as potentially indicating somatotroph cell proliferation. Research suggests these findings might indicate that GHRH-R-mediated signaling, when sustained via a stabilized GRF(1-29) analog, may support somatotroph gene expression and cellular maintenance in GH-deficient preclinical models. These observations may inform the design of experimental systems investigating the relationship between GHRH-R engagement and somatotroph population dynamics.

 

Ipamorelin: GHS-R1a Selectivity and Somatotroph Pharmacology

Pivotal preclinical research by Raun et al. (1998)^[10] characterized Ipamorelin’s pharmacological profile across in vitro murine pituitary cell cultures and conscious mammalian research models. In primary murine pituitary cell preparations, Ipamorelin released GH with a potency and maximal efficacy comparable to GHRP-6 (EC₅₀ approximately 1.3 ± 0.4 nmol/L). In conscious mammalian research models, GH release was concentration-dependent, with an ED₅₀ of approximately 2.3 ± 0.03 nmol/kg and a maximal implication (Emax) of 65 ± 0.2 ng GH/mL plasma.

Specificity profiling across pituitary hormone endpoints indicated that Ipamorelin did not produce measurable elevations in follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), or thyroid-stimulating hormone (TSH). Critically, plasma ACTH and cortisol concentrations were not significantly altered relative to those observed following GHRH stimulation alone, even at experimental concentrations exceeding 200-fold the GH-releasing ED₅₀.^[10] Research suggests this selectivity profile might distinguish Ipamorelin from earlier GHS-R1a agonists such as GHRP-6 and GHRP-2, which are associated with ACTH and cortisol co-elevation, and may support its relevance as a precision tool for investigating GH axis modulation without concurrent hypothalamic-pituitary-adrenal axis perturbation.

 

Convergent GH Axis Stimulation: GHRH-R and GHS-R1a Dual Engagement

The mechanistic basis for combining Modified GRF 1-29 with Ipamorelin rests on the pharmacological complementarity of their receptor systems at the somatotroph level.^[6][10] GHRH-R stimulation by Modified GRF 1-29 elevates intracellular cAMP through Gαs-adenylate cyclase coupling, activating PKA-mediated transcriptional regulation of GH gene expression. GHS-R1a stimulation by Ipamorelin engages the Gq/G11-PLC-IP₃-Ca²⁺ cascade, mobilizing intracellular calcium stores and promoting GH vesicle exocytosis. These pathways converge at the level of somatotroph GH secretory machinery through mechanistically distinct but complementary intracellular routes.

Preclinical and in vitro data examined across GHS-R1a and GHRH-R literature suggest that concurrent receptor stimulation may produce somatotroph GH secretory responses that research indicates might exceed those attributable to single-receptor stimulation alone. This potential synergy is proposed to arise from the non-overlapping second messenger pathways engaged by the two receptor systems, with cAMP and calcium-dependent mechanisms acting in concert to amplify GH pulse amplitude. The inclusion of Fragment 176-191 alongside these two GH-axis modulators may provide a direct adipocyte-level lipolytic mechanism that complements indirect GH-mediated implications on visceral adipose tissue, potentially supporting a multi-pathway investigational approach to adipose metabolism research.^[12]

 

Fragment 176-191 in Oncological Research Contexts

A molecular docking and in vitro investigation examined whether Fragment 176-191 might support the pharmacological activity of doxorubicin in breast cancer cell models. In silico docking simulations characterized the binding affinities of Fragment 176-191 to breast cancer-associated receptor targets and evaluated the implications of its binding on doxorubicin’s interaction with the same receptor systems. In vitro viability assays employing MCF-7 breast cancer cells were conducted to evaluate the anti-proliferative activity of doxorubicin-loaded chitosan nanoparticles co-loaded with Fragment 176-191.^[12]

Findings suggested that dual-loaded nanoparticle preparations exhibited greater anti-proliferative activity against MCF-7 cells than doxorubicin-loaded preparations alone, with investigators proposing that Fragment 176-191 may facilitate multi-target engagement of doxorubicin within cancer cells.^[12] Research suggests these preliminary in vitro observations might indicate a possible auxiliary role for Fragment 176-191 in compound delivery research contexts, though this line of investigation remains at an early exploratory stage and warrants further characterization in controlled experimental models.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. doi:10.1210/endo.142.12.8522. PMID: 11713213. Available from: https://pubmed.ncbi.nlm.nih.gov/11713213/
2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi:10.1159/000053183. PMID: 11146367. Available from: https://pubmed.ncbi.nlm.nih.gov/11146367/
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. Available from: https://www.jofem.org/index.php/jofem/article/view/157
4. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. Available from: https://www.jofem.org/index.php/jofem/article/view/213/278
5. National Center for Biotechnology Information. PubChem Compound Summary for CID 71300630, AOD-9604 (Frag 176-191). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Aod-9604
6. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286. PMID: 15817669. Available from: https://pubmed.ncbi.nlm.nih.gov/15817669/
7. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683. Available from: https://academic.oup.com/jcem/article-abstract/91/3/799/2843281
8. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006. PMID: 16670156. Available from: https://pubmed.ncbi.nlm.nih.gov/16670156/
9. National Center for Biotechnology Information. PubChem Compound Summary for CID 56841945, Modified GRF (1-29). 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/56841945
10. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552. PMID: 9849822. Available from: https://pubmed.ncbi.nlm.nih.gov/9849822/
11. National Center for Biotechnology Information. PubChem Compound Summary for CID 9831659, Ipamorelin. 2024. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
12. Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, et al. Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:1963-1974. doi:10.2147/DDDT.S367586. Available from: https://doi.org/10.2147/DDDT.S367586